GLAXF News and Press, GlaxoSmithKline Plc From 03/06/23

2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...

Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...

Summary Anda's revenue generated $450 million for the company in the last three months of 2022, up $95 million from Q4 2022, driven by substantially increased demand for the company's services. Teva's European segment profit was $1,496 million in 2022, slightly up year-over-year, even t...

Summary Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. The market may move up and down irrationally and seemingly on a whim while our...

Summary Lyell Immunopharma is a US biotechnology developer of innovative therapies for various types of cancer. Shares are falling in trend and headwinds could continue due to lost glamour for the portfolio. LYEL stock should not earn much more than a Sell rating. But when there's n...

Summary Alector, Inc. has a lot of cash for a small biotech, but it is also trading at cash. Alector, Inc. has a late-stage program in a CNS indication and major big pharma deals. The situation, to say the least, is confusing. Alector, Inc. (ALEC) is a pioneering CNS disea...

Summary As predicted by some epidemiologists at the onset of the pandemic, COVID-19 would become an endemic flu-like condition not warranting mandated concern. The growth in sales of COVID-19 therapies and diagnostics was not secular, and plummeting Xevudy sales of GSK take the specialt...

GSK plc (GSK) Q4 2022 Earnings Conference Call February 01, 2023, 06:00 ET Company Participants Nick Stone - Head, Global Investor Relations Emma Walmsley - CEO & Director Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Wa...

Summary Haleon's consumer brands are strong, and its free cash flow margin is high at 16%. Net debt to EBITDA is expected to decrease to 3x in 2024. Although the decline in the value of the pound has had an unfavorable effect on net debt, the company is using free cash flow to reduc...